Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. (COCP) on April 20, 2020, covering events that occurred on April 15, 2020. The company is a Delaware corporation with its principal executive offices in Bothell, WA, and its common stock trades on The Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding corporate governance changes and does not contain financial statements. Consequently, the filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The filing reports the following material changes to the Board of Directors effective April 15, 2020:
- Resignation: Dr. Jane Hsiao resigned as a director, effective immediately. She previously served on the Compensation Committee and chaired the Corporate Governance and Nominating Committee.
- Election: The Board elected Dr. Roger Kornberg, Chairman of the Company's Scientific Advisory Board, as a director to fill the vacancy created by Dr. Hsiao's resignation.
- Committee Appointments: Dr. Kornberg was appointed to the Compensation Committee and the Corporate Governance and Nominating Committee.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary regarding business operations. It explicitly states there are no related party transactions between the Company and Dr. Kornberg reportable under Item 404(a) of Regulation S-K, and no arrangement or understanding existed regarding his selection as a director.
Key Facts for Investor Verification
- Verify the impact of the leadership change on the Compensation and Corporate Governance committees.
- Review the press release furnished as Exhibit 99.1 for additional context on the resignation and election.
- Confirm that no undisclosed related party transactions exist with the new director, Dr. Roger Kornberg.